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Purpose: Although stereotactic ablative body radiotherapy (SABR) is widely used therapeutic technique, predictive factors of 
radiation pneumonitis (RP) after SABR remain undefined. We aimed to investigate the predictive factors affecting RP in patients 
with primary or metastatic lung tumors who received SABR. 
Materials and Methods: From 2012 to 2015, we reviewed 59 patients with 72 primary or metastatic lung tumors treated with 
SABR, and performed analyses of clinical and dosimetric variables related to symptomatic RP. SABR was delivered as 45–60 Gy in 3–4 
fractions, which were over 100 Gy in BED when the α/β value was assumed to be 10. Tumor volume and other various dose volume 
factors were analyzed using median value as a cutoff value. RP was graded per the Common Terminology Criteria for Adverse 
Events v4.03. 
Results: At the median follow-up period of 11 months, symptomatic RP was observed in 13 lesions (12 patients, 18.1%), including 
grade 2 RP in 11 lesions and grade 3 in 2 lesions. Patients with planning target volume (PTV) of ≤14.35 mL had significantly lower 
rates of symptomatic RP when compared to others (8.6% vs. 27%; p = 0.048). Rates of symptomatic RP in patients with internal 
gross tumor volume (iGTV) >4.21 mL were higher than with ≤4.21 mL (29.7% vs. 6.1%; p = 0.017).
Conclusions: The incidence of symptomatic RP following treatment with SABR was acceptable with grade 2 RP being observed in 
most patients. iGTV over 4.21 mL and PTV of over 14.35 mL were significant predictive factors related to symptomatic RP. 
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Introduction
Stereotactic ablative body radiotherapy (SABR) has been widely 
used in the treatment of early-stage primary lung cancers due 
to its high local control rates of approximately 90% or more 
[1]. In addition, SABR is also used to treat metastatic lung 
tumors in the oligometastatic setting as salvage therapy [2]. 
Along with increasing the application of SABR, we also need 
to evaluate the factors relating to SABR associated toxicity, 
especially radiation pneumonitis (RP) [3,4]. However, there 
are limited reports on the predictive factors for developing 
RP after treatment with SABR for primary or metastatic lung 
tumors. Previous reports showed that the incidence of RP 
ranges from 9% to 28%, mostly of grade 2 or less [5]. 
Dose-volume values are potential factors that could 
predict the development of RP after treatment with SABR. 
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In conventional fractionation, the Quantitative Analysis of 
Normal Tissue Effects in the Clinic (QUANTEC) recommends a 
V20 of ≤30% to 35% and a mean lung dose (MLD) of ≤20 to 
23 Gy to reduce the risks of developing RP to less than 20% 
[6]. In some studies, size of target, V20–V25 of bilateral lung 
dose or MLD has been shown as a possible predictive factor of 
symptomatic pneumonitis [7-11]. However, there are no clear 
guidelines for the dose-volume limits for treatment with SABR. 
As tissues irradiated with high fraction doses are expected to 
show different radiobiologic responses, it is difficult to predict 
the possibility of developing RP by using traditional dosimetric 
guidelines [12]. 
In this study, we aim to determine the clinical and dose-
volume factors that affect the development of symptomatic 
RP after treatment of primary or metastatic lung tumors with 
SABR, to facilitate the application of SABR in practical settings.
Materials and Methods
1. Study design
This study was approved by the Yonsei University Health 
System Institutional Review Board (No. 4-2017-0108).
We retrospectively reviewed data on patients with 
primary and metastatic lung tumors who underwent 
treatment with SABR from March 2012 to March 2015 in 
our institution. Inclusion criteria were as follows: age above 
20 years, histologically confirmed primary lung cancers and 
histologically or radiologically diagnosed as metastatic lung 
tumors, and an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–1. For selection of eligible patients, 
we reviewed medical records, laboratory results, and imaging 
studies. Finally, we retrieved 72 tumors from 59 patients with 
primary lung cancers (n = 29) and metastatic lung tumors (n 
= 43). The locations of these lung tumors were divided into 
central versus peripheral lesions, according to the Radiation 
Therapy Oncology Group (RTOG) 0813 protocol [13]; central 
lesions are defined as the tumors located at <2 cm from the 
proximal bronchial tree, or with a planning target volume 
(PTV) touching the mediastinum, or both. Non-central lesions 
are considered as peripheral tumors. Single lesion was treated 
for 46 patients and 2 lesions for 13 patients. Each of 2 lesions 
were located in the opposite lung separately and treated with 
radiotherapy at the interval of 6 months or more. As SABR is 
characterized by steep dose fall off we decided to analyze by 
72 lesions.
2. Procedure for SABR 
All patients underwent simulation computed tomography (CT) 
with immobilizing devices, such as, a whole-body vacuum lock 
or a stereotactic body frame, and an abdominal compressor 
for respiration control. A shallow breathing technique using 
Abches (APEX Medical Inc., Tokyo, Japan) was also applicable 
for patients who were intolerant to the body compressor. 
If the respiratory diaphragm moved over 1 cm vertically, 
the abdominal compressor or shallow breath technique 
using Abches were indicated for LINAC multiport group and 
intensity-modulated radiotheray (IMRT) group. All patients 
underwent four-dimensional CT (4D-CT) scans to track the 
movement of the target along the respiratory movement. 
For SABR, the gross tumor volume (GTV) was delineated in 
every phase of the 4D-CT images, and the PTV was defined 
as the internal gross tumor volume (iGTV) with a 5- to 10-
mm margin. In patients treated with CyberKnife (Accuray Inc., 
Sunnyvale, CA, USA), whole-body vacuum lock was used for 
the stability of patients during treatment. However abdominal 
compressor or Abches was not indicated as CyberKnife can 
track the tumor along the respiratory movement. PTV for 
patients treated with CyberKnife group was minimized to 2–3 
mm. Four dose schemes were used according to the tumor 
location and volume, and were administered as 48 Gy in 4 
fractions (fx), 45 Gy in 3 fx, 60 Gy in 4 fx, and 60 Gy in 3 fx; 
these were prescribed to the volumetric PTV and the primary 
aim was to cover 100% volume of the PTV with 80% isodose 
line of the prescribed dose. When converted to biologically 
equivalent dose (BED), these doses are 106 Gy, 113 Gy, 150 Gy, 
and 180 Gy when the α/β value of the tumor is assumed to 
be 10 Gy. All patients were treated every other day. Specific 
prescriptions of SABR doses are shown in Table 1.
Different planning systems according to treatment modality 
are used and specific name of planning systems are as follows; 
Pinnacle3 treatment planning system (Philips Radiation 
Oncology Systems, Milpitas, CA, USA) for LINAC multiport 
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LINAC, linear accelerator; VMAT, volume modulated arc therapy; 
fx, fraction.
Predictive factors of symptomatic radiation pneumonitis after SABR
165www.e-roj.orghttps://doi.org/10.3857/roj.2017.00066
group, RayStation (RaySearch Laboratories AB, Stockholm, 
Sweden) for volumetric modulated arc therapy (VMAT) group, 
TomoTherapy treatment planning system (Accuray Inc.) for 
TomoTherapy group, and Multiplan Treatment Planning System 
v2.05 (Accuray Inc.) for CyberKnife group.
Normal organ dose constraints for SABR are based on the 
report of the American Association of Physicists in Medicine 
Task Group 101 (AAPM TG 101) [14]. Dose constraints for 
specific organ are as follows: 12 Gy/3 fx and 13 Gy/4 fx for 
MLD, V20 <10% for bilateral lung, 39 Gy for great vessel and 15 
Gy for trachea and bronchial tree.
Delivery quality assurances for each patient and each 
radiation treatment were done before start of treatment, and 
the use of 4D cone beam CT (Symmetry) or megavoltage CT 
for accurate delivery were also mandatory. When tumors were 
treated with CyberKnife (Accuray Inc.), a tracking system was 
applied. As we do not insert gold fiducial markers, tumors 
visible on either one or both X-ray cameras were indicated for 
treatment with CyberKnife. Patients who could not tolerate 
the duration of treatment and had non-trackable lesions were 
excluded from the indication for treatment.
3. Assessment of radiation pneumonitis
Patients were assessed through regular follow-up visits, 
and underwent chest CT scans at 1, 3, and 6 months after 
undergoing treatment with SABR. Per the decision of 
the physician, positron emission tomography-computed 
tomography (PET-CT) scans were also available at 3 to 6 
months after treatment with SABR, particularly for metastatic 
lung tumors, to confirm the extent of disease. RP was graded 
in 5 levels per the Common Terminology Criteria for Adverse 
Events (CTCAE) ver 4.03 [15,16]. RP was diagnosed based on 
clinical symptoms and radiologic findings, which develop 
within 6 months after undergoing treatment with SABR 
[16,17]. We assessed symptomatic RP that was defined as 
grade 2 or worse, and analyzed the predictive factors related 
to symptomatic RP. 
4. Data analysis and statistical method
We measured PTV (in mL), iGTV (in mL), tumor diameter (in 
cm), MLD (in Gy), bilateral V5, V10, V15, V20, V25, V30, V35, and V40 
(in %). Vd is defined as the volume of the bilateral normal lung 
that received a radiation dose of over ‘d’ Gy. Target volumes, 
lung volumes, and Vd were measured using MIM software 
(MIM Software Inc., Cleveland, OH, USA). Potential predictive 
factors for the occurrence of an RP event were: patient age, 
sex, the ECOG performance status, smoking history, underlying 
pulmonary disease, pathology, tumor location, fraction size 
and total dose of SABR, PTV, the number of targets, and 
dosimetric parameters, such as, ipsilateral and contralateral 
MLD, and V5–V40 in increments of 5 Gy. 
We used median value as the cutoff values of iGTV, PTV, 
tumor diameter, MLD, and Vd for statistic analysis. Chi-
square test was used for univariable analysis for all variables. 
Characteristics which are found to be significant and V20/V25 
were entered in stepwise method in a binary logistic regression 
analysis to develop multivariate model. SPSS ver. 20.0 (IBM, 
Armonk, NY, USA) was used for the analysis, and a p-value of 
<0.05 was defined as statistically significant.
Results
1. Characteristics of patients, tumors, and treatments 
All baseline characteristics are listed in Table 2. Median 
duration of follow-up was 11 months (range, 6 to 31 months). 
Twenty-nine lesions (40.3%) were primary lung cancers, and 
the others were metastatic sites (59.7%). Forty-two lesions 
(58.3%) were on the left lung, and the remaining were on the 
right side. Eighteen lesions (25%) were in the central area. 
Forty-six patients were treated for single lesion with SABR, 
while 13 patients were treated for 2 lung lesions. The 2 lesions 
were located in the opposite lung and they were treated with 
SABR at intervals of more than 6 months. Median iGTV was 4.21 
mL (range, 0.23 to 36.43 mL) and the PTV was 14.35 mL (range, 
3.33 to 78.61 mL). 
Median time of treatment was 7 days (range, 4 to 12 days). 
The individual radiation treatment schemes were as follows: 
31 lesions treated with 45 Gy in 3 fx, 12 lesions with 48 Gy in 
4 fx, 14 lesions with 60 Gy in 4 fx, and 15 lesions with 60 Gy 
in 3 fx. All irradiated doses to normal organs were acceptable, 
according to the report of AAPM TG 101. 
2. Incidence of symptomatic RP 
During the median follow-up period, symptomatic RP 
developed in 13 lesions (12 patients, 18.1%). Of these patients, 
11 had grade 2 RP and two had grade 3 RP with a median 
onset of 14 weeks (range, 4 to 24 weeks) from the starting 
date of radiotherapy. No patients showed RP of grade 4 or 
higher. All patients with RP over grade 2 achieved symptomatic 
relief with conservative management and the use of steroid 
agents. One patient with grade 3 RP is shown in Fig. 1 with 
radiologic image.
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3. Predictive factors for symptomatic RP
The predictive factors associated with the development of RP 
were analyzed, and both iGTV and PTV were established as 
significant predictive factors. The detailed analyses of clinical 
factors related to symptomatic RP are shown in Table 3, and 
that of dosimetric factors in Table 4.
In multivariate analysis, there were significant differences 
in the incidence of symptomatic RP in patients with PTV of 
≤14.35 mL compared to those with PTV of >14.35 mL (8.6% vs. 
27%; p = 0.048). Additionally iGTV of ≤4.21 mL was significant 
cut off value for the reduced incidence of RP (6% vs. 30%; 
p = 0.017) (Table 5). Other factors such as patient age, sex, 
the ECOG performance status, smoking history, underlying 
pulmonary disease, pathology, tumor location, fraction size 
and total dose of SABR, MLD, the number of treated targets 
and tumor diameter did not show association with the 
development of symptomatic RP. Dosimetric factors, including 
V5, V10, V15, V20, V25, V30, V35, and V40, were not significant 
predictive factors that influenced symptomatic RP. 
The incidence of pneumonitis between patients with single 
lesion and 2 lesions was not different (21.7% vs.11.5%; p = 
0.352).
4. Dose-volume values and the incidence of RP according 
to the radiation treatment modalities
We analyzed the incidence of symptomatic RP and dose-
volume factors according to the 4 treatment modalities: the 
Fig. 1. An 82-year-old woman with asthma was diagnosed with 
adenocarcinoma of the left lower lung, which was classified as 
cT1bN0M0 per TNM system of classification (A). Due to old age 
and impaired cardiac function, SABR was delivered as a total dose 
of 60 Gy in 3 fractions, as an alternative to surgery. SABR was 
delivered with 14 non-coplanar beams to the lesion in the left 
lower lung (B). She underwent a CT scan of the chest at 1 month 
(C) and 3 months (D) after undergoing treatment with SABR. 
She had no complaints, and both CT scans showed no abnormal 
signs related to radiation pneumonitis. However, after 5 months 
of SABR, she developed dyspnea, and underwent a CT scan of 
her chest for the evaluation of dyspnea. Newly developed pleural 
effusion with consolidation was observed, and diagnosed as 
radiation pneumonitis of grade 3 (E). SABR, stereotactic ablative 
body radiotherapy; CT, computed tomography.
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Lung mass size profiles
 Tumor diameter (cm)
 iGTV (mL)
 PTV (mL)
  63 (22–86)
  40 (67.8)
  19 (32.2)
  29 (49.2)
  15 (25.4)
  6 (10.2)
  4 (6.8)
  4 (6.8)
  1 (1.7)
  46 (78.0)
  13 (22.0)
  33 (55.9)
  26 (44.1)
  23 (39.0)
  36 (61.0)
  2 (3.4)
  57 (96.6)
  13 (18.1)
  7 (9.7)
  10 (13.9)
  24 (33.3)
  18 (25)
  18 (25)
  54 (75)
  2.0 (0.8–4.1)
  4.21 (0.23–36.43)
  14.35 (3.33–78.61)
Values are presented as median (range) or number (%).
ILD, interstitial lung disease; RUL, right upper lobe; RML, right 
middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left 
lower lobe; iGTV, internal gross tumor volume; PTV, planning tar-
get volume.
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LINAC multiport, VMAT, TomoTherapy, and CyberKnife with 
tumor tracking system. There was no difference of incidence 
of symptomatic RP and dosimetric values between modalities. 
No patients who were treated with CyberKnife suffered 
from symptomatic RP, although the PTV, MLD, and V5–V40 in 
this group were not significantly different from the LINAC 
multiport group.
Discussion and Conclusion
Acute RP is a common side effect of radiation treatment 
that can significantly affect the quality of life of patients, by 
inducing chronic respiratory problems and sometimes death, 
therefore, many studies have reported the predictive factors 
related to RP [18-21]. However, in SABR or SBRT, there is no 
clear consensus for predicting the risk of RP in relation to the 
clinical and dosimetric factors. In this study, we showed that a 
value of iGTV of over 4.21 mL and PTV of over 14.35 mL were 
significant factors for developing acute symptomatic RP after 
treatment of primary lung cancers and metastatic lung tumors 
with SABR. 
Some recent studies have suggested predictive factors 
of RP after treatment with SABR for lung tumors. We have 
summarized previous studies that dealt with the dose-volume 
factors related to RP in Table 6. A group from the Netherlands 
Vrije University reported that almost three times the incidence 
of symptomatic RP (10% vs. 28%) appeared after treatment 
with SABR when the PTV was over 80 cm3 [22]. In 251 patients 
of node negative stage I–IIB non-small cell lung cancers 
(NSCLCs), Barriger et al. [7] reported predictive factors of grade 
Table 3. Predictive factor univariate analysis of symptomatic RP
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Values are presented as number (%).
RP, radiation pneumonitis; fx, fraction; iGTV, internal gross tumor 
volume; PTV, planning target volume; LINAC, linear accelerator; 
IMRT, intensity-modulated radiotherapy; VMAT, volumetric modu-
lated arc therapy.
Table 4. Predictive factor univariate analyses of symptomatic RP 
according to V5–V40 of bilateral normal lung parenchyme (n = 72)
Variable RP No RP p-value
V5 (%)
  <15.00
  ≥15.00 
V10 (%)
  <8.76




























































Values are presented as number (%).
RP, radiation pneumonitis; Vd (%), volume of bilateral normal lung 
that received a dose of over ‘d’ Gy.
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≥2 RP when treated with SABR. In this study, MLD >4 Gy and 
V20 >4% were significant factors for RP, although PTV was not 
a significant risk factor for the development of symptomatic 
RP. In addition, Matsuo et al. [5] showed that PTV, V20, and 
V25 were independent predictive factors of symptomatic RP 
for patients diagnosed with stage I NSCLCs who received 
SABR with 48 Gy in 4 fractions. Interestingly, there was a 
study of Ong et al. [23] reporting that contralateral lung V5 
significantly affect the development of symptomatic RP. 
Comparted to other reported literatures in Table 6, crude rate 
of 18.1% of grade ≥2 pneumonitis in our study is somewhat 
higher. This can be explained by a strict symptom control 
in our clinic. All patients presenting clinical symptoms with 
suspicious radiologic changes at follow-up are recommended 
to use steroid agents and this might have resultes in an 
overestimation of the incidence. In agreement with other 
studies, there were limited incidence of grade >2 pneumonitis 
in our study also; two cases of grade 3 RP and no grade 4 or 5.
In our study, only tumor and target size were significant 
factors related to symptomatic RP. Meaning of other dose 
volume factors such as MLD and V5–V40 (%) might have 
been diluted as the prescription dose and fraction number 
were different for each lesion treatment modality was not a 
significant predictive factor for RP. PTV size between LINAC 
multiport group and IMRT group was significantly different 
(20.0 mL vs. 11.7 mL; p = 0.019) and this is the reason that 
more people suffered symptomatic RP in LINAC multiport 
group, without significance (25.6% vs. 10.9%; p = 0.19).
As we mentioned above, many studies failed to suggest 
common dose volume factors of cutoff values which are 
critical to the development of RP. Thus, in general, both the 
volume reduction of the target (significant predictive factor 
in our study) and the dose restriction for bilateral lungs after 
treatment of lung tumors with SABR is recommended. In 
practice, based on other reports including those of our study, 
most radiation oncologists are trying to reduce the PTV and 
irradiated dose to normal lungs in many aspects. Firstly, 4D-
CT simulation is gaining popularity for targeting moving 
organs, especially the lungs. The 4D-CT leads to 10 phases of 
images per the respiration cycle, and it reflects the movement 
of the target organs. These moving images may increase the 
certainty of the target, and lead to a reduction of unnecessary 
PTV margins. To specifically reduce the respiratory movement, 
the use of a body compressor or shallow breathing technique 
with Abches is also applicable. In this study, such devices were 
used with the vertical movement of the respiratory diaphragm 
over 1 cm, for selected patients who could tolerate them. 
Furthermore, 4D cone beam CT was available before delivery 
and this makes it possible for us to reduce the PTV margins 
[24,25]. Finally, the technique of real-time tumor tracking was 
applied to the trackable tumor using CyberKnife, which can 
reduce the safety margins [26]. Despite the small number of 
cases in our study, we found that patients who are treated 
with CyberKnife did not suffer from symptomatic RP, even 
though the PTVs, V5–V40 values, and small fraction numbers 
were comparable with those of the LINAC multiport group. 
Additionally, we found that the rate of incidence of RP 
above grade 3 was very low (3%) within 6 months after 
treatment with SABR, and this rate is comparable to that 
observed in other studies [27,28]. When the rates of toxicities 
of over grade 3 are compared to other modalities of treatment, 
such as surgery, SABR emerges as a potentially safer and more 
tolerable choice for patients. Chang et al. [1] reported the 
occurrence of grade 3–5 toxicities corresponding to treatment 
methods in stage I NSCLCs. In the group of patients treated 
with SABR, three patients (10%) had grade 3 toxicities, two 
had dyspnea or cough, three had chest wall pain, and one 
had a rib fracture. In the group of patients that underwent 
Table 5. Multivariate analysis of predictive factor analyses of 
symptomatic RP (n = 72)




























































Values are presented as number (%).
RP, radiation pneumonitis; iGTV, internal gross tumor volume; PTV, 
planning target volume; Vd (%), volume of bilateral normal lung 
that received a dose of over ‘d’ Gy; LINAC, linear accelerator; IMRT, 
intensity-modulated radiotherapy; VMAT, volumetric modulated 
arc therapy.
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lobectomies, one patient died of surgical complications, and 12 
(44%) developed grade 3–4 toxicities related to treatment. 
This study has some limitations. Firstly, the follow-up 
period in this study is short. However, it appears that a 
median follow-up period of 11 months is enough, upon the 
consideration that symptoms of RP generally appear at a 
median time of 5 months after treatment with SABR [8,10]. 
Secondly, deficient data on pulmonary function tests and pre-
radiotherapy interventions may have compromised the quality 
of our data set. We could not suggest the performance of 
quantitative pulmonary function tests on patients before and 
after undergoing SABR because the pulmonary function test 
is not a mandatory examination for patients with metastatic 
tumors and for those who do not express discomfort or other 
symptoms. Thirdly, we lack data on patient previous thorax 
area surgery history which can damage lung parenchyme and 
induce fibrotic changes of lung. Thus our data cannot verify 
whether interventions or surgeries themselves influenced the 
development of RP.
In conclusion, the incidence of symptomatic RP following 
treatment with SABR was acceptable, with most patients 
showing RP of grade 1 or 2; there were no patients with 
grade 4 RP. Additionally, we found that both the large PTV 
and iGTV were predictive factors related to the development 
of symptomatic RP after treatment with SABR. Therefore, 
selected patients with small volumes of lung tumors, advanced 
RT techniques, such as respiratory gating and tracking systems, 
and appropriate dose prescriptions corresponding to tumor 
sizes are recommended for safer treatments with SABR. In the 
future, clinical trials with larger number of patients or meta-
analyses of previous studies would be helpful for establishing 
the indications of the predictive factors that affect RP in lung 
tumors treated with SABR.
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